Companion Spine closed its $60.1 million Series A funding round with a final closing of a $5.0 million top-off, bringing the total in Series A to $60.1 million.
Funds will support global expansion of both the DIAM implant for the treatment of degenerative disc disease and LISA, the device obtained through the acquisition of Backbone earlier in 2023, as well as the premarket approval submission process for DIAM and APERIUS, an intervertebral implant for the percutaneous treatment of lumbar stenosis.
Erick Cloix, CEO and co-founder of Companion Spine, said, “The final closing of the capital raise supports our comprehensive solutions portfolio that precisely addresses, over time, the different stages and the multiple origins of back pain. Our unique portfolio of technologies enables interventional, earlier, safer, and scalable treatment to match the exact patient condition as it is today, or will be tomorrow, and after tomorrow.“
Companion Spine closed its $60.1 million Series A funding round with a final closing of a $5.0 million top-off, bringing the total in Series A to $60.1 million.
Funds will support global expansion of both the DIAM implant for the treatment of degenerative disc disease and LISA, the device obtained through the acquisition of Backbone...
Companion Spine closed its $60.1 million Series A funding round with a final closing of a $5.0 million top-off, bringing the total in Series A to $60.1 million.
Funds will support global expansion of both the DIAM implant for the treatment of degenerative disc disease and LISA, the device obtained through the acquisition of Backbone earlier in 2023, as well as the premarket approval submission process for DIAM and APERIUS, an intervertebral implant for the percutaneous treatment of lumbar stenosis.
Erick Cloix, CEO and co-founder of Companion Spine, said, “The final closing of the capital raise supports our comprehensive solutions portfolio that precisely addresses, over time, the different stages and the multiple origins of back pain. Our unique portfolio of technologies enables interventional, earlier, safer, and scalable treatment to match the exact patient condition as it is today, or will be tomorrow, and after tomorrow.“
Copy to clipboard 
